Stock Analysts’ updated eps estimates for Wednesday, September 6th:

CONSOL Energy (NYSE:CNX) had its buy rating reissued by analysts at Stifel Nicolaus. The firm currently has a $24.00 target price on the stock, down from their previous target price of $26.00.

Duluth Holdings (NASDAQ:DLTH) had its buy rating reissued by analysts at DA Davidson. They currently have a $25.00 target price on the stock.

Dunkin’ Brands Group (NASDAQ:DNKN) had its hold rating reaffirmed by analysts at BMO Capital Markets.

Equity Residential (NYSE:EQR) had its hold rating reiterated by analysts at BMO Capital Markets. The firm currently has a $68.00 price target on the stock.

FedEx Corporation (NYSE:FDX) had its buy rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $245.00 price target on the stock.

HCP (NYSE:HCP) had its hold rating reaffirmed by analysts at BMO Capital Markets. The firm currently has a $32.00 target price on the stock.

HeidelbergCement AG (ETR:HEI) had its buy rating reaffirmed by analysts at DZ Bank AG.

At Home Group (NASDAQ:HOME) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $28.00 target price on the stock, up from their previous target price of $23.00.

Hewlett Packard Enterprise (NYSE:HPE) had its buy rating reissued by analysts at Jefferies Group LLC. The firm currently has a $17.50 price target on the stock, down from their previous price target of $22.00.

MBIA (NYSE:MBI) had its buy rating reissued by analysts at BTIG Research. They currently have a $14.00 target price on the stock.

Nabors Industries (NYSE:NBR) had its hold rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a $8.00 target price on the stock.

Pfizer (NYSE:PFE) had its buy rating reaffirmed by analysts at BMO Capital Markets. The firm currently has a $37.00 price target on the stock.

Dave & Buster’s Entertainment (NASDAQ:PLAY) had its outperform rating reaffirmed by analysts at Wells Fargo & Company. They currently have a $71.00 price target on the stock, down from their previous price target of $78.00.

Revance Therapeutics (NASDAQ:RVNC) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $50.00 price target on the stock. The analysts wrote, “Today Revance announced that Mark Foley has been appointed to the Board of Directors, effective 9/5/17.””

Zoetis (NYSE:ZTS) had its buy rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $75.00 price target on the stock.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.